Metastatic screening for patients with newly diagnosed breast cancer : who and how?

Simple item page
dc.contributor.authorEdge, Jennyen_ZA
dc.contributor.authorBudge, Melissaen_ZA
dc.contributor.authorWebner, Adielen_ZA
dc.contributor.authorDoruyter, Alexanderen_ZA
dc.contributor.authorCilliers, Glenen_ZA
dc.contributor.authorMalherbe, Francoisen_ZA
dc.date.accessioned2020-04-21T07:59:44Z
dc.date.available2020-04-21T07:59:44Z
dc.date.issued2020-04-06
dc.descriptionCITATION: Edge, J. et al. 2020. Metastatic screening for patients with newly diagnosed breast cancer : who and how? South African Journal of Oncology, 4:a94, doi:10.4102/sajo.v4i0.94.
dc.descriptionThe original publication is available at https://sajo.org.za
dc.description.abstractBackground: Staging for breast cancer patients, as defined by the American Joint Committee on Cancer (AJCC), has historically been limited to anatomical staging. However, the eighth version of the AJCC guidelines has been altered to include tumour biology. Anatomical staging still has a place especially in low-middle income countries where the majority of patients present with locally advanced or metastatic disease. Aim: This review article considers which newly diagnosed breast cancer patients should be referred for anatomical staging and the pros and cons of the different modalities available in South Africa. Method: The different modalities available were reviewed with respect to metastatic screening for asymptomatic women. The usefulness of the modalities were considered with reference to organ-specific disease rather than the stage of the patient. Results: Any person with newly diagnosed breast cancer and symptoms suggestive of systemic involvement should be investigated. All symptomatic women who present with a tumour larger than 5 cm, radiological or clinical evidence of nodal disease, triple negative or HER2+ve tumours should have metastatic screening. This gives information about the primary as well as the metastatic status. Conclusion: However, increasingly, the major determinant of treatment is the biology of the cancer and not the anatomical stage. In future, this trend is likely to increase with anatomical staging becoming less important.en_ZA
dc.description.urihttps://sajo.org.za/index.php/sajo/article/view/94
dc.description.versionPublisher's version
dc.format.extent6 pagesen_ZA
dc.identifier.citationEdge, J. et al. 2020. Metastatic screening for patients with newly diagnosed breast cancer : who and how? South African Journal of Oncology, 4:a94, doi:10.4102/sajo.v4i0.94.
dc.identifier.issn2523-0646 (online)
dc.identifier.issn2518-8704 (print)
dc.identifier.otherdoi:10.4102/sajo.v4i0.94
dc.identifier.urihttp://hdl.handle.net/10019.1/107715
dc.language.isoen_ZAen_ZA
dc.publisherAOSISen_ZA
dc.rights.holderAuthors retain copyrighten_ZA
dc.subjectBreast canceren_ZA
dc.subjectMetastatic diseaseen_ZA
dc.subjectBreast cancer — diagnosisen_ZA
dc.subjectMedical screening — Guidelinesen_ZA
dc.titleMetastatic screening for patients with newly diagnosed breast cancer : who and how?en_ZA
dc.typeArticleen_ZA
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
edge_metastatic_2020.pdf
Size:
537.16 KB
Format:
Adobe Portable Document Format
Description:
Download article
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Research Articles (Surgery)